^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Mesothelin-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) (NCT06051695)
    Phase 1/2
    A2 Biotherapeutics Inc.
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/03/2024
    Primary completion :
    06/01/2028
    Completion :
    06/01/2029
    HLA-A • MSLN
    |
    MSLN expression • HLA-A*02
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (NCT02414269)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/01/2015
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    PD-L1 • MSLN
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (NCT05568680)
    Phase 1
    Verismo Therapeutics
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/30/2023
    Primary completion :
    03/15/2026
    Completion :
    03/30/2026
    MSLN
    |
    MSLN expression
    |
    SynKIR-110
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (NCT05617755)
    Phase 1
    Arsenal Biosciences, Inc.
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    11/29/2022
    Primary completion :
    12/01/2024
    Completion :
    02/01/2027
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (NCT04577326)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    09/30/2020
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells
    CAR T Cells in Mesothelin Expressing Cancers (NCT03054298)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    01/24/2024
    Initiation :
    04/06/2017
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    PD-L1
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • TmMSTN-01
    A Study of TAK-103 in Adult With Solid Tumors (NCT05164666)
    Phase 1
    Takeda
    Active, not recruiting
    Last update posted :
    12/27/2023
    Initiation :
    01/05/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    MSLN
    |
    MSLN expression
    |
    NIB103
    Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors (NCT05089266)
    Phase 1
    Shanghai Cell Therapy Group Co.,Ltd
    Recruiting
    Last update posted :
    07/17/2023
    Initiation :
    11/30/2021
    Primary completion :
    07/30/2024
    Completion :
    01/30/2025
    PD-L1 • MSLN
    |
    PD-L1 expression
    |
    BZD1901
    Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer (NCT05372692)
    Phase N/A
    Weijia Fang, MD
    Completed
    Last update posted :
    07/17/2023
    Initiation :
    04/12/2022
    Primary completion :
    02/01/2023
    Completion :
    02/01/2023
    MSLN
    |
    LD013
    Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors (NCT05944185)
    Phase 1/2
    Shanghai Cell Therapy Group Co.,Ltd
    Not yet recruiting
    Last update posted :
    07/14/2023
    Initiation :
    09/01/2023
    Primary completion :
    09/01/2024
    Completion :
    09/01/2025
    PD-L1 • MSLN
    |
    PD-L1 expression
    |
    BZD1901
    UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (NCT05848999)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    05/12/2023
    Initiation :
    04/27/2023
    Primary completion :
    05/01/2025
    Completion :
    07/01/2025
    IL6 • MSLN • IL10
    |
    cyclophosphamide • UCLM802
    MSLN-targeted CAR-T Cells in Solid Tumors. (NCT05783089)
    Phase 1
    Cancer Institute and Hospital, Chinese Academy ...
    Not yet recruiting
    Last update posted :
    03/24/2023
    Initiation :
    04/01/2023
    Primary completion :
    04/01/2025
    Completion :
    04/01/2027
    IL6 • MSLN • IL10
    |
    UCLM802
    UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (NCT05775666)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    03/20/2023
    Initiation :
    03/01/2023
    Primary completion :
    05/01/2024
    Completion :
    01/01/2025
    IL6 • MSLN • IL10
    |
    cyclophosphamide • UCLM802
    Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (NCT05531708)
    Phase 1
    Shanghai Pudong Hospital
    Withdrawn
    Last update posted :
    03/01/2023
    Initiation :
    04/02/2021
    Primary completion :
    04/30/2025
    Completion :
    04/30/2026
    MSLN
    |
    cyclophosphamide • fludarabine IV • UCLM802
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT05373147)
    Phase 1
    Shanghai Mengchao Cancer Hospital
    Recruiting
    Last update posted :
    10/26/2022
    Initiation :
    10/30/2020
    Primary completion :
    02/01/2023
    Completion :
    08/01/2023
    PD-L1 • PD-1 • IL6 • MSLN • IL2 • IL10
    |
    PD-L1 expression
    |
    BZD1901
    Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05141253)
    Phase 1
    Tongji Hospital
    Recruiting
    Last update posted :
    04/27/2022
    Initiation :
    01/12/2022
    Primary completion :
    11/01/2023
    Completion :
    11/01/2036
    MSLN
    |
    MSLN positive
    |
    RD133
    MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (NCT05344976)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    04/25/2022
    Initiation :
    04/14/2022
    Primary completion :
    10/14/2024
    Completion :
    02/01/2026
    EGFR • ALK • MET • ROS1 • MSLN
    |
    ALK positive • EGFR positive • EGFR negative • MSLN positive
    |
    YTS105
    An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05166070)
    Phase 1
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    12/21/2021
    Initiation :
    01/01/2022
    Primary completion :
    01/01/2024
    Completion :
    01/01/2037
    MSLN
    |
    MSLN positive
    |
    RD133
    Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto) (NCT04981691)
    Phase 1
    Ruijin Hospital
    Recruiting
    Last update posted :
    09/17/2021
    Initiation :
    10/01/2021
    Primary completion :
    01/09/2022
    Completion :
    07/09/2022
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • UCLM802
    Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    02/04/2021
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    12/01/2021
    HLA-A • MSLN • CTAG1B
    |
    HLA-A*02:01 • MSLN positive • HLA-A positive
    |
    cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (NCT03545815)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    08/10/2020
    Initiation :
    03/19/2018
    Primary completion :
    10/30/2020
    Completion :
    12/30/2020
    MSLN
    |
    MSLN positive
    |
    GC008t • MPTK-CAR-T cells • MSLN CAR-T
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT04503980)
    Phase 1
    Shanghai Cell Therapy Group Co.,Ltd
    Recruiting
    Last update posted :
    08/07/2020
    Initiation :
    03/26/2020
    Primary completion :
    03/01/2021
    Completion :
    06/01/2022
    PD-L1 • MSLN
    |
    PD-L1 expression
    |
    cyclophosphamide • BZD1901
    αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors (NCT04489862)
    Phase 1
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    07/28/2020
    Initiation :
    05/13/2020
    Primary completion :
    06/01/2022
    Completion :
    12/01/2022
    PD-L1 • MSLN
    |
    PD-L1 expression
    |
    cyclophosphamide • BZD1901
    Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
    Phase 1/2
    Shenzhen BinDeBio Ltd.
    Recruiting
    Last update posted :
    12/11/2019
    Initiation :
    03/01/2018
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
    |
    HLA-A*02:01 • CD19 expression • HLA-A positive
    |
    cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
    MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913)
    Phase 1
    Zhejiang University
    Unknown status
    Last update posted :
    04/10/2019
    Initiation :
    04/10/2019
    Primary completion :
    10/01/2021
    Completion :
    04/01/2022
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
    Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors (NCT03747965)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    11/20/2018
    Initiation :
    11/01/2018
    Primary completion :
    11/01/2019
    Completion :
    05/01/2020
    MSLN
    |
    MSLN positive
    |
    paclitaxel • cyclophosphamide • GC008t
    PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST) (NCT03615313)
    Phase 1/2
    Shanghai Cell Therapy Research Institute
    Unknown status
    Last update posted :
    08/03/2018
    Initiation :
    08/06/2018
    Primary completion :
    08/03/2020
    Completion :
    12/03/2020
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • fludarabine IV • BZD1901
    Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. (NCT03267173)
    Phase 1
    First Affiliated Hospital of Harbin Medical Uni...
    Unknown status
    Last update posted :
    08/30/2017
    Initiation :
    06/15/2017
    Primary completion :
    06/01/2019
    Completion :
    06/01/2019
    HER-2 • PSCA
    |
    mesothelin-targeted CAR-T immunotherapy
    Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors (NCT02930993)
    Phase 1
    China Meitan General Hospital
    Unknown status
    Last update posted :
    10/12/2016
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2018
    Completion :
    08/01/2019
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells
    A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (meso-CART) (NCT02706782)
    Phase 1
    Shanghai GeneChem Co., Ltd.
    Unknown status
    Last update posted :
    03/11/2016
    Initiation :
    03/01/2016
    Primary completion :
    02/01/2018
    Completion :
    09/01/2018
    MSLN
    |
    MSLN expression
    |
    cyclophosphamide • meso-CART